Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
NS-229 by Nippon Shinyaku for Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Likelihood of Approval
NS-229 is under clinical development by Nippon Shinyaku and currently in Phase II for Granulomatosis with Polyangiitis (Wegener's Granulomatosis). According...
Data Insights
Brogidirsen by Nippon Shinyaku for Duchenne Muscular Dystrophy: Likelihood of Approval
Brogidirsen is under clinical development by Nippon Shinyaku and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData,...